# Eledon Pharmaceuticals, Inc.: Form 10-Q for the period ended Mar 31, 2016

- Company: [Eledon Pharmaceuticals, Inc.](/companies/eldn.md) (CIK 1404281)
- Form: 10-Q
- Filed: 2016-05-10
- Accepted by EDGAR: May 10, 2016, 07:08 ET
- Period: 2016-03-31
- Accession: 0001193125-16-584673
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1404281/000119312516584673/d183124d10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1404281/000119312516584673/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2016-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2016-01-01 to 2016-03-31 | $0 | us-gaap:SalesRevenueGoodsNet |
| Research and development | 3 months, 2016-01-01 to 2016-03-31 | $7.9m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2016-01-01 to 2016-03-31 | −$11.5m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2016-01-01 to 2016-03-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2016-01-01 to 2016-03-31 | −$11.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2016-01-01 to 2016-03-31 | −$0.51 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 3 months, 2016-01-01 to 2016-03-31 | −$9.7m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 3 months, 2016-01-01 to 2016-03-31 | $17.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2016-03-31 | $14.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2016-03-31 | $57.0m | us-gaap:AssetsCurrent |
| Total assets | at 2016-03-31 | $57.7m | us-gaap:Assets |
| Current liabilities | at 2016-03-31 | $6.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2016-03-31 | $6.3m | us-gaap:Liabilities |
| Shareholders' equity | at 2016-03-31 | $51.4m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 32,748 characters.

*The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and the audited financial statements and notes thereto and management’s discussion and analysis of financial condition and results of operations for the year ended December 31, 2015 included in our Annual Report on Form 10-K that was filed with the SEC on March 10, 2016. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business, includes forward looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the ‘‘Risk Factors’’ section of our Annual Report on Form 10-K, our actual results could differ materially from the results described in, or implied by, these forward-looking statements.*

### Overview

We are a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases. Our lead drug candidate, galeterone, is an oral small molecule that utilizes the mechanistic pathways of current second-generation androgen signaling inhibitors, while also introducing a distinct third mechanism – androgen receptor degradation. We are developing galeterone for the treatment of patients with metastatic castration resistant prostate cancer, or mCRPC.

We are conducting a pivotal Phase 3 clinical trial comparing galeterone to Xtandi® (enzalutamide) in approximately 148 treatment-naïve mCRPC patients whose prostate tumors express the AR-V7 splice variant. We refer to this clinical trial as ARMOR3-SV. We believe that the AR-V7 splice variant is the most common form of C-terminal loss, or the loss of the portion of the androgen receptor that contains the ligand-binding domain. C-terminal loss generally, and AR-V7 specifically, has been associated with poor response to commonly-used oral therapies for mCRPC. ARMOR3-SV is, to our knowledge, the first precision-medicine based pivotal clinical trial in prostate cancer. Selection of patients with AR-V7 is made using a clinical trial assay developed by our collaborator, Qiagen Manchester Limited, or Qiagen. We believe that the design of ARMOR3-SV is aligned with feedback that we obtained from the U.S. Food and Drug Administration, or FDA, and the European Medicines Agency. We expect to complete enrollment in ARMOR3-SV by the end of 2016 and to have top-line data available from the study by mid-2017. We have been given fast track designation by the FDA for galeterone for the treatment of mCRPC.

As of March 31, 2016, galeterone has been well tolerated in prostate cancer patients and healthy volunteers in clinical trials. In these trials, which included patients whose tumor cells did not express AR-V7, clinically meaningful reductions in levels of prostate specific antigen or PSA, a biochemical marker used to evaluate prostate cancer patients for signs of response to therapy, have been observed in prostate cancer patients treated with galeterone. Therefore, and subject to the availability of resources, we anticipate expanding the clinical development of galeterone in other indications or patient populations.

Our planned expansion of the galeterone clinical development program is focused on mCRPC patients who have shown resistance following treatment with either Xtandi or Zytiga® (abiraterone acetate). During the first quarter of 2016, we began enrolling patients in an expansion of an arm of our ongoing Phase 2 clinical trial of galeterone, referred to as ARMOR2, in mCRPC patients who have developed acquired resistance to Xtandi. We also expect to evaluate galeterone beginning in mid-2016 in men whose mCRPC rapidly progressed after initial treatment with either Xtandi or Zytiga. We plan to evaluate these “rapid progressors” for the presence of AR-V7 without it being a criterion for participation.

We have worldwide development and commercialization rights to galeterone. To maximize the value of these rights, we intend to build a urology- and oncology-focused specialty sales and marketing organization in the United States to support the commercialization of galeterone. We intend to commercialize galeterone outside the United States through collaborations with third parties.

Since our inception in March 2004, we have devoted substantially all of our resources to developing our product candidates, building our intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. To date, we have financed our operations primarily through our initial public offering of our common stock, and prior to our initial public offering, through private placements of our redeemable convertible preferred stock and convertible promissory notes. In September 2014, we completed the initial public offering of our common stock through the issuance and sale of 6,480,000 shares of our common stock at a price to the public of $15.00 per share, resulting in net proceeds of $87.1 million after deducting underwriting discounts and commissions and offering expenses. In October 2014, we issued and sold an additional 540,000 shares of our common stock as a result of the partial exercise by the underwriters of their option to purchase additional shares of common stock at the public offering price of $15.00 per share, and received additional net proceeds of $7.5 million after deducting underwriting discounts and commissions.

We have never generated any revenue and have incurred net losses in each year since our inception. Our net loss was $11.4 million for the three months ended March 31, 2016 and $45.1 million for the year ended December 31, 2015. As of March 31, 2016, we had an accumulated deficit of $142.9 million. This deficit has resulted principally from costs incurred in connection with research and development activities, general and administrative costs associated with our operations and in-licensing our product candidates. We expect to continue to incur significant expenses and increasing operating losses for at least the next several years. We anticipate that our expenses will increase substantially if and as we:

- conduct ARMOR3-SV and other clinical trials, non-clinical studies and formulation development and manufacturing activities required to support the submission of a new drug application, or NDA, to the FDA for galeterone for AR-V7 positive mCRPC;
- develop a companion diagnostic test for use with galeterone in collaboration with Qiagen;
- conduct planned additional clinical trials of galeterone in mCRPC patients who have shown resistance following treatment with either Xtandi or Zytiga;
- develop galeterone for the treatment of other indications and patient populations in prostate cancer;
- explore the use of galeterone for the treatment of other diseases that are associated with the androgen receptor signaling pathway;
- identify and develop compounds that are designed to disrupt androgen receptor signaling through enhanced androgen receptor degradation;
- enter into agreements with third parties to manufacture galeterone;
- establish a sales, marketing and distribution infrastructure to support the commercialization of galeterone in the United States;
- maintain, expand and protect our intellectual property portfolio;
- continue our other research and development efforts;
- acquire or in-license additional compounds or technologies; and
- operate as a public company.

Our ability to generate product revenue, which we do not expect will occur for at least the next several years, if ever, will depend heavily on the successful development and eventual commercialization of galeterone and other product candidates that we may develop in the future. As a result, we will need additional financing to support our continuing operations until such time that we can generate significant revenue from product sales, if ever. We expect to finance our operations through a combination of equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements. We may be unable to raise capital when needed or on acceptable terms, which would force us to delay, limit, reduce or terminate our research and development programs or commercialization efforts. We will need to generate significant revenue to achieve profitability, and we may never do so.

As of March 31, 2016, we had cash and investments of $54.3 million. We expect that our existing cash and investments will only be sufficient to enable us to fund our planned operating expenses and capital expenditure requirements into the first half of 2017. We will need to obtain substantial additional funding in order to complete the development of, and to commercialize, galeterone for patients with AR-V7 positive mCRPC and in other indications and patient populations, submit an NDA to the FDA for galeterone, conduct other ongoing and planned clinical trials of galeterone, and develop or commercialize any future product candidates. If we are unable to raise capital when needed or on acceptable terms, we may be forced to delay, reduce, terminate or eliminate our product development programs and our commercialization efforts. See “—Liquidity and Capital Resources.”

### Financial Operations Overview

### Revenue

To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the near future. If our development efforts for galeterone or other product candidates that we may develop in the future are successful and result in regulatory approval or license or collaboration agreements with third parties, we may generate revenue in the future from a combination of product sales or payments from collaboration or license agreements that we may enter into with third parties.

### Operating Expenses

The majority of our operating expenses consist of research and development activities and general and administrative costs.

### Research and Development Expenses

Research and development expenses, which consist primarily of costs associated with our product research and development efforts, include the following:

- third-party contract costs relating to research, formulation and manufacturing, preclinical studies and clinical trial activities;
- third-party contract costs relating to development of a companion diagnostic test for use with galeterone, including the AR-V7 clinical trial assay being used to identify eligible patients for ARMOR3-SV;
- personnel costs, including salaries, related benefits and stock-based compensation for personnel engaged in research and development functions;
- consulting fees paid to third parties;
- costs related to compliance with regulatory requirements;
- payments made under our third-party licensing agreements; and
- allocated facility-related costs.

We typically use our employee and infrastructure resources across our development programs. We track outsourced development costs by product candidate or development program, but we do not allocate personnel costs, payments made under our licensing agreements or other internal costs to specific development programs or product candidates. These costs are included in unallocated research and development expenses in the tables below. See “Results of Operations.”

Research and development activities are central to our business. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. To date, we have focused substantially all of our research and development efforts on the development of galeterone. We incurred total research and development expenses of $7.9 million for the three months ended March 31, 2016 and $10.6 million for the three months ended March 31, 2015. We expect that our research and development expenses will increase as we conduct ARMOR3-SV, other clinical trials, and additional NDA-enabling activities for galeterone, and develop any future product candidates.

We are currently conducting ARMOR3-SV, our pivotal Phase 3 clinical trial of galeterone, and are expanding our clinical development program for galeterone. We cannot determine with certainty the duration and completion costs of ARMOR3-SV, our expanded program for galeterone, or any future clinical trials of any future product candidates we develop or if, when, or to what extent we will generate revenue from the commercialization and sale of any of our product candidates that obtain regulatory approval. We may never succeed in achieving regulatory approval for any of our product candidates. The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors, including:

- the scope, rate of progress, expense and results of our ongoing clinical trials as well as any additional clinical trials and other research and development activities that we may conduct;
- future clinical trial results;
- uncertainties in clinical trial design and patient enrollment rate;
- significant and changing government regulation and regulatory guidance;
- the timing and receipt of any regulatory approvals; and
- the expense of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights.

A change in the outcome of any of these variables with respect to the development of galeterone or any future product candidates could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we anticipate will be required for the completion of clinical development of a product candidate, if we experience significant delays in patient enrollment in any of our clinical trials, or if we are required to make any changes to the formulation of, or the manufacturing process for, a product candidate, we could be required to expend significant additional financial resources and time on the completion of development and receipt of regulatory approval.

### General and Administrative Expenses

General and administrative expenses consist of personnel costs, including salaries, related benefits and stock-based compensation expense, of our executive, finance, business and corporate development and other administrative functions. General and administrative expenses also include professional fees for auditing, tax and legal services, including legal expenses to pursue protection of our intellectual property, pre-commercialization costs, insurance costs, travel expenses and allocated facility-related costs.

We expect that our general and administrative expenses will continue to increase in future periods as we establish capabilities that would enable the potential commercialization of galeterone for the treatment of mCRPC and of any future product candidates, and as a result of increased expenses associated with being a public company and costs incurred to seek collaborations with respect to galeterone and any other product candidates that we may develop in the future.

### Interest Income and Other Income (Expense), net

Interest income and other income (expense), net, consists of interest income and miscellaneous income and expense unrelated to our core operations. Interest income consists of interest earned on our cash and investments. Our interest income has not been significant due to low interest earned on invested balances.

### Income Taxes

Since our inception in 2004, we have not recorded any U.S. federal or state income tax benefits for either the net losses we have incurred or our earned research and development tax credits, due to the uncertainty of realizing a benefit from those items in the future. As of December 31, 2015, we had federal and state net operating loss carryforwards of $27.9 million and $24.2 million respectively. Our federal and state net operating loss carryforwards begin to expire in 2024 and 2030, respectively. We also had federal and state research and development tax credit carryforwards of $1.0 million and $0.4 million, respectively, as of December 31, 2015, which begin to expire in 2025 and 2023, respectively. Our federal and state net operating loss carryforwards do not yet include the effect of research and development expenses of $96.1 million that we have capitalized for income tax purposes as of December 31, 2015.

### Critical Accounting Policies and Significant Judgments and Estimates

Our financial statements are prepared in accordance with generally accepted accounting principles in the United States. The preparation of our financial statements and related disclosures requires us to make estimates, assumptions and judgments that affect the reported amount of assets, liabilities, revenue, costs and expenses, and related disclosures. We believe that of our critical accounting policies described under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies and Significant Judgments and Estimates” in our Annual Report on Form 10-K for the year ended December 31, 2015, the following involve the most judgment and complexity:

- accrued research and development costs; and
- stock-based compensation.

Accordingly, we believe the policies set forth above are critical to fully understanding and evaluating our financial condition and results of operations. If actual results or events differ materially from the estimates, judgments and assumptions used by us in applying these policies, our reported financial condition and results of operations could be materially affected.

There have been no material changes in these policies since December 31, 2015.

### Results of Operations

### Comparison of the Three Months Ended March 31, 2016 and 2015

The following table summarizes our results of operations for the three months ended March 31, 2016 and 2015:

*(in thousands)*

|  | Three Months Ended March 31, 2016 | 2015 | Change |
| --- | ---: | ---: | ---: |
| Revenue | $— | $— | $— |
| Operating expenses: |  |  |  |
| Research and development | 7,931 | 10,559 | (2,628) |
| General and administrative | 3,549 | 2,741 | 808 |
| Total operating expenses | 11,480 | 13,300 | (1,820) |
| Loss from operations | (11,480) | (13,300) | 1,820 |
| Interest income and other income (expense), net | 54 | 40 | 14 |
| Net loss | $(11,426) | $(13,260) | $1,834 |

### Research and Development Expenses

*(in thousands)*

|  | Three Months Ended March 31, 2016 | 2015 | Change |
| --- | ---: | ---: | ---: |
| Galeterone for prostate cancer | $6,042 | $9,272 | $(3,230) |
| Other early-stage development programs and additional indications for galeterone | 323 | 103 | 220 |
| Unallocated research and development expenses | 1,566 | 1,184 | 382 |
| Total research and development expenses | $7,931 | $10,559 | $(2,628) |

The decrease in research and development expenses associated with our galeterone for prostate cancer program for the three months ended March 31, 2016 compared to the three months ended March 31, 2015 was due primarily to decreased costs associated with the development of our AR-V7 clinical trial assay of $2.3 million and decreased manufacturing costs of $1.7 million, partially offset by an increase in costs of clinical trials of $0.7 million. Costs associated with the development of our AR-V7 clinical trial assay for the three months ended March 31, 2015 included a one-time fee paid for the exclusive right to have the circulating tumor cell enrichment technology used in the assay and related companion diagnostic test as well as higher assay development costs. The decrease in manufacturing costs was primarily due to a large purchase of raw materials in the three months ended March 31, 2015 for use in manufacturing process optimization and validation studies required to support the submission of an NDA for galeterone. The increase in clinical trial costs for the three months ended March 31, 2016 primarily related to ARMOR3-SV, which was initiated in the second quarter of 2015.

### General and Administrative Expenses

*(in thousands)*

|  | Three Months Ended March 31, 2016 | 2015 | Change |
| --- | ---: | ---: | ---: |
| Personnel related (including stock-based compensation) | $1,926 | $1,243 | $683 |
| Professional and consultant fees | 1,089 | 974 | 115 |
| Facility related and other | 534 | 524 | 10 |
| Total general and administrative expenses | $3,549 | $2,741 | $808 |

The increase in personnel related costs for the three months ended March 31, 2016 compared to the three months ended March 31, 2015 was primarily due to an increase in headcount in the general and administrative function associated with operating as a public company including an increase in stock-based compensation expense of $0.3 million related to this increase in headcount.

### Liquidity and Capital Resources

Since our inception in March 2004, we have not generated any revenue and have incurred recurring net losses. We anticipate that we will continue to incur losses for at least the next several years. We expect that our research and development and general and administrative expenses will continue to increase and, as a result, we will need additional capital to fund our operations, which we may obtain from additional financings, research funding, collaborations, contract and grant revenue or other sources.

To date, we have funded our operations primarily through our initial public offering of our common stock and, prior to our initial public offering, private placements of our redeemable convertible preferred stock and convertible promissory notes. In September 2014, we completed the initial public offering of our common stock through the issuance and sale of 6,480,000 shares of our common stock at a price to the public of $15.00 per share, resulting in net proceeds of $87.1 million after deducting underwriting discounts and commissions and offering expenses. In October 2014, we issued and sold an additional 540,000 shares of our common stock as a result of the partial exercise by the underwriters of their option to purchase additional shares of common stock at the public offering price of $15.00 per share and received additional net proceeds of $7.5 million after deducting underwriting discounts and commissions.

### Cash Flows

As of March 31, 2016, our principal sources of liquidity were cash and investments of $54.3 million.

The following table summarizes our sources and uses of cash and cash equivalents for each of the periods presented:

*(in thousands)*

|  | Three Months Ended March 31, 2016 | 2015 |
| --- | ---: | ---: |
| Cash used in operating activities | $(9,740) | $(11,104) |
| Cash used in investing activities | (17) | (45) |
| Cash provided by financing activities | 37 | 55 |
| Net decrease in cash and cash equivalents | $(9,720) | $(11,094) |

*Operating activities*. During the three months ended March 31, 2016, cash used in operating activities consisted of our net loss of $11.4 million, partially offset by net non-cash charges of $1.1 million and by net cash provided by changes in our operating assets and liabilities of $0.6 million. Our net non-cash charges during the period consisted almost entirely of stock-based compensation expense of $1.0 million. Cash provided by changes in our operating assets and liabilities consisted primarily of a decrease in prepaid expenses and other current assets of $0.5 million during the three months ended March 31, 2016.

During the three months ended March 31, 2015, cash used in operating activities consisted of our net loss of $13.3 million, partially offset by net non-cash charges of $0.6 million and by net cash provided by changes in our operating assets and liabilities of $1.6 million. Our net non-cash charges during the period consisted primarily of stock-based compensation expense of $0.6 million. Cash provided by changes in our operating assets and liabilities consisted primarily of a net increase in accounts payable and accrued expenses of $1.5 million during the three months ended March 31, 2015.

Our prepaid expenses and other current assets and accounts payable and accrued expense balances have historically been affected by the volume of business and the timing of vendor invoicing and payments.

*Investing activities*. We used a small amount of cash during the three months ended March 31, 2016 and 2015 related to purchases of property and equipment.

*Financing activities*. During the three months ended March 31, 2016, net cash provided by financing activities was attributable to proceeds from the exercise of stock options. During the three months ended March 31, 2015, net cash provided by financing activities was due to the repayment of notes receivable and proceeds from the exercise of stock options.

### Capital Requirements

Galeterone is still in clinical development. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. We anticipate that our expenses will increase substantially if and as we:

- conduct ARMOR3-SV and other clinical trials, non-clinical studies, and formulation development and manufacturing activities required to support the submission of an NDA to the FDA for galeterone for AR-V7 positive mCRPC;
- develop a companion diagnostic test for use with galeterone in collaboration with Qiagen;
- conduct planned additional clinical trials of galeterone in mCRPC patients who have shown resistance following treatment with either Xtandi or Zytiga;
- develop galeterone for the treatment of other indications and patient populations in prostate cancer;
- identify and develop compounds that are designed to disrupt androgen receptor signaling through enhanced androgen receptor degradation;
- enter into agreements with third parties to manufacture galeterone;
- establish a sales, marketing and distribution infrastructure to support the commercialization of galeterone in the United States;
- maintain, expand and protect our intellectual property portfolio;
- continue our other research and development efforts;
- acquire or in-license additional compounds or technologies; and
- operate as a public company.

As of March 31, 2016, we had cash and investments of $54.3 million. We expect that our existing cash and investments will only be sufficient to enable us to fund our planned operating expenses and capital expenditure requirements into the first half of 2017. We will need to obtain substantial additional funding in order to complete the development of, and to commercialize, galeterone for patients with AR-V7 positive mCRPC and in other indications and patient populations, submit an NDA to the FDA for galeterone, conduct other ongoing and planned clinical trials of galeterone, and develop or commercialize any future product candidates. If we are unable to raise capital when needed or on acceptable terms, we may be forced to delay, reduce, terminate or eliminate our product development programs and our commercialization efforts.

We have based these estimates on assumptions that may prove to be wrong, as we may use our available capital resources sooner than we currently expect or our clinical trials may take longer than we anticipate. Because of the numerous risks and uncertainties associated with the development of galeterone and because the extent to which we may enter into collaborations with third parties for development of galeterone is unknown, we are unable to estimate the amounts of increased capital outlays and operating expenses associated with completing the research and development of galeterone.

Our future capital requirements will depend on many factors, including:

- the progress and results of ARMOR3-SV and our efforts to complete the clinical development of galeterone and conduct other non-clinical, formulation development and manufacturing activities required to submit an NDA to the FDA and marketing authorization applications to regulatory authorities outside of the United States;
- the progress and results of any additional clinical trials of galeterone that we decide to conduct in other indications and patient populations, including in our planned trials in patients whose mCRPC has progressed after treatment with either Xtandi or Zytiga;
- the timing and outcome of regulatory review of galeterone for the treatment of AR-V7 positive mCRPC and in any other indication or patient population, and of any other future product candidates;
- the progress and results of the development of a companion diagnostic test for use with galeterone in collaboration with Qiagen;
- the cost of commercialization activities, including product sales, marketing, manufacturing and distribution, for galeterone and our future product candidates for which we receive regulatory approval;
- the development of future product candidates, including our plans to seek to acquire or in-license additional compounds or technologies;
- revenue, if any, received from commercial sales of galeterone and any future product candidates, should any of our product candidates be approved by the FDA or a similar regulatory authority outside the United States;
- our ability to establish collaborations on favorable terms, if at all, particularly arrangements to develop, market and distribute galeterone and any future product candidates outside the United States; and
- the cost of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims.

Until such time, if ever, that we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. To this end, in October 2015, we filed and the SEC declared effective a shelf registration statement registering an aggregate of $150 million in various equity and debt securities. We have not issued or sold any securities under this registration statement. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that could adversely affect the rights of our common stockholders. Debt financing, if available, may involve agreements that require liens to be placed on our property and include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends and may require the issuance of warrants, which could potentially dilute our common stockholders’ ownership interest. If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or current or future product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market galeterone that we would otherwise prefer to develop and market ourselves.

### Contractual Obligations and Commitments

There have been no material changes to our contractual obligations and commitments outside the ordinary course of business from those described under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Contractual Obligations and Commitments” in our Annual Report on Form 10-K for the year ended December 31, 2015.

### Off-Balance Sheet Arrangements

We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules.

### Recently Issued Accounting Pronouncements

A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is set forth in Note 2 to the financial statements included in this Quarterly Report on Form 10-Q.

## Market risk

As filed, 672 characters.

### Interest Rate Fluctuation Risk

Our cash and investments as of March 31, 2016 consisted of cash, money market accounts, certificates of deposit and government bonds. The primary objectives of our investment activities are to preserve principal, provide liquidity and maximize income without significantly increasing risk. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of interest rates. Because of the short-term nature of the instruments in our portfolio, a sudden change in market interest rates would not be expected to have a material impact on our financial condition or results of operations.

## Controls and procedures

As filed, 2,120 characters.

### Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2016. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of March 31, 2016, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

### Changes in Internal Control over Financial Reporting

No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 247 characters.

There have been no material changes in the Company’s risk factors from those previously disclosed in Part I, Item 1A, “*Risk Factors”* in our Annual Report on Form 10-K for the year ended December 31, 2015, as filed with the SEC on March 10, 2016.

Filed May 10, 2016.
Source: SEC EDGAR, the filing index for accession 0001193125-16-584673. Last ingested by Listed: Nov 13, 2026, 16:16 ET. No prices; not investment advice.
